Novartis research leader takes the helm at Forty Seven, a CIRM-backed fledgling already deep in the clinic
Menlo Park, CA-based Forty Seven launched well ahead of the game compared to most any other biotech upstart. When the company was spun out of the lab of Stanford’s legendary Irv Weissman a year ago with a $75 million Series A from a syndicate including Google’s venture arm, their anti-CD47 antibody Hu5F9-G4 was already in a pair of early-stage trials. And last week the company added an impressive CEO, grabbing Novartis’ head of biosimilar development at Sandoz, Mark McCamish, for the helm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
